Advances in Cancer Treatment: Targeted Therapies and Immunotherapies Show Promising Results

Strategic Insights -

Current research on cancer treatment has shown significant improvements in outcomes for patients, thanks to the shift from traditional chemotherapy to targeted therapies and immunotherapies. Regulatory agencies have approved several targeted therapies for specific genetic mutations, leading to better results for various diseases. A recent study conducted at the University of Campania Luigi Vanvitelli in Naples, Italy, analyzed the use of off-label drugs in 83 adult patients with solid tumors, finding promising results for early-line off-label treatment.

Key Takeaways:

  • The study involved 83 adult patients with solid tumors, with an average age of 63 years and a slight male majority.
  • The most common molecular testing method was next-generation sequencing (NGS), and immunotherapy was the predominant treatment (67%).
  • The median progression-free survival (PFS) was 3.4 months (95% CI 2.0-4.5 months), and the median overall survival (OS) was 10 months (95% CI 7.5-12.2 months).
  • Early-line off-label treatment showed a trend toward longer PFS compared with later lines.
  • The study highlights the importance of molecular tumor boards and multidisciplinary collaboration in selecting off-label treatments.
  • Regulatory and ethical challenges notwithstanding, off-label drug use offers significant therapeutic opportunities, necessitating well-designed clinical trials and registries to better understand their efficacy and safety.

Statistics:

  • 83 adult patients with solid tumors were involved in the study.
  • The average age of patients was 63 years.
  • 42% of patients had upper gastrointestinal cancers.
  • 21% of patients had colorectal carcinoma.
  • 67% of patients received immunotherapy as the predominant treatment.
  • The median PFS was 3.4 months (95% CI 2.0-4.5 months).
  • The median OS was 10 months (95% CI 7.5-12.2 months).

Sources:

  • Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach. ESMO Real World Data and Digital Oncology, 2025,7():100108.
  • https://doi-org.sdpl.idm.oclc.org/10.1016/j.esmorw.2024.100108 (free version of journal article available)